Literature DB >> 12582162

The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3.

Yong Li1, Ken Inoki, Panayiotis Vacratsis, Kun-Liang Guan.   

Abstract

Tuberous sclerosis complex (TSC) is a genetic disease caused by mutations in either TSC1 or TSC2 tumor suppressor genes. TSC1 and TSC2 (also known as hamartin and tuberin, respectively) form a functional complex and negatively regulate cell growth by inhibiting protein synthesis. 14-3-3 binds to TSC2 and may inhibit TSC2 function. We have reported previously that phosphorylation of serine 1210 (Ser(1210)) in TSC2 is essential for 14-3-3 binding. Here we show that serum and anisomycin enhance the interaction between TSC2 and 14-3-3 by stimulating phosphorylation of Ser(1210). Activation of p38 MAP kinase (p38) is essential for the stimulating effect of serum and anisomycin although p38 is not directly responsible for the phosphorylation of Ser(1210) in TSC2. Both in vitro and in vivo experiments demonstrate that the p38-activated kinase MK2 (also known as MAPKAPK2) is directly responsible for the phosphorylation of Ser(1210). Our data show that anisomycin stimulates phosphorylation of Ser(1210) of TSC2 via the p38-MK2 kinase cascade. Phosphorylation of TSC2 by MK2 creates a 14-3-3 binding site and thus regulates the cellular function of the TSC2 tumor suppressor protein.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12582162     DOI: 10.1074/jbc.M300862200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  Escherichia coli succinic thiolinase. Stoichiometry of phosphorylation and coenzyme A binding.

Authors:  C M Bowman; J S Nishimura
Journal:  J Biol Chem       Date:  1975-07-25       Impact factor: 5.157

Review 2.  ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.

Authors:  Philippe P Roux; John Blenis
Journal:  Microbiol Mol Biol Rev       Date:  2004-06       Impact factor: 11.056

Review 3.  Regulation of TOR by small GTPases.

Authors:  Raúl V Durán; Michael N Hall
Journal:  EMBO Rep       Date:  2012-02-01       Impact factor: 8.807

4.  S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response.

Authors:  Keng Po Lai; Wai Fook Leong; Jenny Fung Ling Chau; Deyong Jia; Li Zeng; Huijuan Liu; Lin He; Aijun Hao; Hongbing Zhang; David Meek; Chakradhar Velagapudi; Samy L Habib; Baojie Li
Journal:  EMBO J       Date:  2010-07-23       Impact factor: 11.598

5.  Acute heat treatment improves insulin-stimulated glucose uptake in aged skeletal muscle.

Authors:  Anisha A Gupte; Gregory L Bomhoff; Chad D Touchberry; Paige C Geiger
Journal:  J Appl Physiol (1985)       Date:  2010-12-09

6.  Amino Acid Activation of mTORC1 by a PB1-Domain-Driven Kinase Complex Cascade.

Authors:  Juan F Linares; Angeles Duran; Miguel Reina-Campos; Pedro Aza-Blanc; Alex Campos; Jorge Moscat; Maria T Diaz-Meco
Journal:  Cell Rep       Date:  2015-08-13       Impact factor: 9.423

7.  A novel cardioprotective p38-MAPK/mTOR pathway.

Authors:  Gonzalo Hernández; Hind Lal; Miguel Fidalgo; Ana Guerrero; Juan Zalvide; Thomas Force; Celia M Pombo
Journal:  Exp Cell Res       Date:  2011-10-02       Impact factor: 3.905

Review 8.  Signaling by target of rapamycin proteins in cell growth control.

Authors:  Ken Inoki; Hongjiao Ouyang; Yong Li; Kun-Liang Guan
Journal:  Microbiol Mol Biol Rev       Date:  2005-03       Impact factor: 11.056

Review 9.  Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences.

Authors:  Hakan Cam; Peter J Houghton
Journal:  Target Oncol       Date:  2011-04-16       Impact factor: 4.493

10.  Phosphorylation of Raptor by p38beta participates in arsenite-induced mammalian target of rapamycin complex 1 (mTORC1) activation.

Authors:  Xiao-Nan Wu; Xue-Kun Wang; Su-Qin Wu; Jiawei Lu; Min Zheng; Yan-Hai Wang; Huamin Zhou; Hongbing Zhang; Jiahuai Han
Journal:  J Biol Chem       Date:  2011-07-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.